Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts - Wikidata - awgldk - TriplyDB

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

http://www.wikidata.org/entity/Q24650581

about

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence Diagnosis and treatment of latent infection with Mycobacterium tuberculosis Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Current approaches to tuberculosis in the United States.New approaches in the diagnosis and treatment of latent tuberculosis infection The use of anti-tuberculosis therapy for latent TB infection Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Eliminating human tuberculosis in the twenty-first century.Current development and future prospects in chemotherapy of tuberculosis Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention New regimens to prevent tuberculosis in adults with HIV infection Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses Antituberculosis drugs and hepatotoxicity.Rifapentine for the treatment of pulmonary tuberculosis.Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice Update in tuberculosis 2006.Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Health-Related Quality of Life, Depression and Anxiety in Hospitalized Patients with Tuberculosis.Update in tuberculosis 2009.Challenges and opportunities in developing novel drugs for TB.Current management options for latent tuberculosis: a review.Tuberculosis and the military.Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail.Tuberculosis in China: A longitudinal predictive model of the general population and recommendations for achieving WHO goals.Rifapentine for the treatment of latent tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

P2860

Q21144660-02013DE8-2801-461F-B622-4CF56E4B657C Q24201325-5A42A808-4C41-4D43-8E09-24341BFD9DF4 Q26777748-45499F52-0CCC-4A1E-B044-D145141DC8B3 Q27021614-05417398-1C75-412F-BC6C-98154D7F7811 Q28479103-1DFD8CFC-BFCD-473E-A9C6-C72692C22067 Q28552736-D81CB951-7114-4390-8F84-479C241934BF Q33165650-CE046502-BCA5-4C7C-ACF9-9C9157D73E86 Q33379045-0005EAC7-4B29-4AFA-A23B-5879AFE175F3 Q33585344-2E856D7E-2863-4863-A3E5-37DAC9E20847 Q33746114-E0FDEFF6-5DDE-457B-9DC1-F934BE7E6F79 Q34090979-37C4385B-1A5D-4F8C-822A-00A77E3FE795 Q34212799-A10F5558-09BE-4C18-BB74-09B4BC31B5BE Q34279727-3F5468CF-2563-4946-97BD-4A52CC03C52B Q34419185-804C94D1-59A9-4256-B649-AEDE05476DCF Q35026573-7246FA9C-44D2-4E56-B301-3093FE383557 Q35527885-D5E14BBA-A6A9-4801-AC23-CE4D54027A03 Q35581410-8E7B655E-A355-4A59-A0CC-7AE92295ECAB Q35705874-F8E74C97-E0C3-4529-8DDE-2256AD5656D5 Q36019231-BA222095-63D0-4EE5-9747-203A8E03D9D7 Q36094233-1782C320-E75B-43CB-ACEB-F63D4F49D33F Q36125227-8436DEA9-B82A-48B8-8CAF-E7672E0B16C8 Q36280305-810808DD-4879-42A4-AD1A-86C22C01A198 Q36343641-C7858CC6-E36E-4517-8464-3C9445687A86 Q36628708-1FC3F995-C837-4D31-A5CF-292CFFA4383A Q36643657-17353F1F-9C51-418F-BEA5-81DF2C9BA177 Q36703065-18813993-C120-4650-B793-049FDD1FAB44 Q36753136-47BCEF0C-32D8-4E31-BF28-816C333BF1C2 Q37114268-4CDE6143-2799-4FD0-AFEF-4262D31F2AB0 Q37265335-0346CE9F-2157-49EB-A927-A53512957096 Q37346929-F2AF71C9-0933-42D1-A79C-8D59D2FE3B39 Q37443290-69F37B7F-70B1-40EA-A087-C1FE9DCE00F5 Q37599981-CE94B405-4F7A-4915-9160-BA73680931EC Q37704062-B992041D-C563-4746-8956-D7E279F784B4 Q37924294-444567B7-6507-4EB9-98A1-E439DCEA88A0 Q38066198-C8B86A66-345F-4186-AD1A-D2BA24CDC3BF Q38151080-CA7F389A-E162-4438-BBFA-802B2E80ADF2 Q38426903-FA96149D-447F-4A93-99D3-20FE8E1038AB Q38757370-C83A4C96-80FB-44E6-BB9A-51C587D5B9DF Q38933165-4C55E686-1B3B-4682-98A7-F18C2BDA69F1 Q40095703-B7FD2986-49B8-4FD2-AFE2-8F91199172A6

P2860

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

http://www.wikidata.org/entity/Q24650581

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@ast

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@en

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@nl

type

label

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@ast

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@en

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@nl

prefLabel

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@ast

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@en

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@nl

P1433

Q24650581-6740AE2F-CD86-49FC-8B3B-C989642DC9A4

P1476

Q24650581-B96EB63F-D191-4E0B-A9E8-FD9254AB1F98

P2093

Q24650581-00C04C9E-E62D-4C8A-AADF-138081248CAF

Q24650581-122DB5A0-65D4-4BEB-8140-40C14389C580

Q24650581-42EA46DF-3447-4F7B-9869-CE7942921D8A

Q24650581-71EEAEF9-5E14-4808-ADEA-07482DEC995A

Q24650581-90BEE544-3805-41D1-AA83-F4CCF8C6E7EE

Q24650581-C33E93B0-20B2-492B-B3B3-FA3B7BC9D2B1

P2860

Q24650581-12456F3B-F5B9-4AF7-92EA-E68829CE64B3

Q24650581-16F162AB-30D9-4403-A113-D3F3871BBFA4

Q24650581-355C992E-0E81-4922-948C-57B67235376A

Q24650581-366849D1-0BA9-4DE8-A292-96D04C8E3707

Q24650581-3CD39932-B8AA-42F0-ABDC-29EA7F315E0B

Q24650581-461A08D5-69F0-4B5A-80DE-3A5C36575F42

Q24650581-47FD49B2-F200-46FA-8ADD-0091D69D6B59

Q24650581-49E9CD8C-CDB7-42F5-A4E1-6EF6C9BB0162

Q24650581-67A8F34B-090B-46F9-A697-BD026DAE6037

Q24650581-731821D4-4542-48A6-A859-BEC286471465

P304

Q24650581-454AAAA3-85EA-437A-B4E1-B6AB1D93696E

P31

Q24650581-074890C3-126F-4E54-96AB-8C53387A92DB

P3181

Q24650581-53C1CE35-D08F-4152-8324-BFCA67C141BA

P356

Q24650581-78D1758F-62A3-42FE-83FC-8E32C6A49629

P407

Q24650581-25BE147A-88EE-4E16-A845-7A839BEB168B

P433

Q24650581-75AFA7A5-EDDE-416B-A7FF-16D39F207D33

P478

Q24650581-29EF2299-12B4-4F67-A04A-7D614C58971B

P50

Q24650581-A627C540-6472-46E8-8E65-E4A8B0935FAA

Q24650581-D54E51B9-230F-403B-9A5C-C48C5BB22269

P577

Q24650581-D53F3989-90CC-454D-8270-7B624AB1CCB5

P698

Q24650581-7C0271DA-D6F3-40D4-B291-C310D23F3491

P921

Q24650581-2BBB1F63-CA1D-4FCE-AE12-943F96675E08

P932

Q24650581-547D0AD1-345D-4513-A895-A2E32EA8C9A4

P3181

P356

RCCM.200512-1953OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Weekly rifapentine/isoniazid o ...... rculosis in household contacts

@en

P2093

Gisely Falco

http://www.w3.org/2001/XMLSchema#string

Grace Link Barnes

http://www.w3.org/2001/XMLSchema#string

Jacqueline S Coberly

http://www.w3.org/2001/XMLSchema#string

José Cláudio Faulhaber

http://www.w3.org/2001/XMLSchema#string

Richard D Moore

http://www.w3.org/2001/XMLSchema#string

Roberto Zajdenverg

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society

Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Epidemiology of hepatitis A and E virus infection in Brazil.

Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.

Controlled chemoprophylaxis trials in tuberculosis. A general review.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Short-course chemoprophylaxis for tuberculosis.

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.

P304

922-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1606076

http://www.w3.org/2001/XMLSchema#string

P356

10.1164/RCCM.200512-1953OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

173

http://www.w3.org/2001/XMLSchema#string

P50

Mauro Schechter

Richard E Chaisson

P577

2006-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16474028

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2662911

http://www.w3.org/2001/XMLSchema#string